Tomasz Skorski
Affiliations: | Microbiology and Immunology | Temple University, Philadelphia, PA, United States |
Area:
Molecular Biology, ImmunologyGoogle:
"Tomasz Skorski"Children
Sign in to add trainee| Lori R. Rink | grad student | 2006 | Temple University |
| Kimberly C. Morales | grad student | 2012 | Temple University |
| Elisabeth S. Bolton | grad student | 2013 | Temple University |
| Yashodhara Dasgupta | grad student | 2014 | Temple University |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Calbert ML, Chandramouly G, Adams CM, et al. (2023) 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. Molecular Cancer Therapeutics |
| Liu ZS, Sinha S, Bannister M, et al. (2023) R-loop accumulation in spliceosome mutant leukemias confers sensitivity to PARP1 inhibition by triggering transcription-replication conflicts. Cancer Research |
| Drzewiecka M, Jaśniak D, Barszczewska-Pietraszek G, et al. (2023) Class I HDAC Inhibition Leads to a Downregulation of FANCD2 and RAD51, and the Eradication of Glioblastoma Cells. Journal of Personalized Medicine. 13 |
| Drzewiecka M, Gajos-Michniewicz A, Hoser G, et al. (2023) Histone Deacetylases (HDAC) Inhibitor-Valproic Acid Sensitizes Human Melanoma Cells to Dacarbazine and PARP Inhibitor. Genes. 14 |
| Sullivan-Reed K, Toma MM, Drzewiecka M, et al. (2023) Simultaneous targeting of DNA polymerase theta and PARP1 or RAD52 triggers dual synthetic lethality in homologous recombination-deficient leukemia cells. Molecular Cancer Research : McR |
| Wolczyk M, Serwa R, Kominek A, et al. (2023) TIAR and FMRP shape pro-survival nascent proteome of leukemia cells in the bone marrow microenvironment. Iscience. 26: 106543 |
| Li H, Chatla S, Liu X, et al. (2023) Haploinsufficiency of ZNF251 causes DNA-PKcs-dependent resistance to PARP inhibitors in BRCA1-mutated cancer cells. Research Square |
| Golovine K, Abalakov G, Lian Z, et al. (2023) ABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias. Blood Cancer Journal. 13: 42 |
| Barszczewska-Pietraszek G, Drzewiecka M, Czarny P, et al. (2022) Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours. International Journal of Molecular Sciences. 24 |
| Vekariya U, Toma MM, Nieborowska-Skorska M, et al. (2022) DNA polymerase theta protects leukemia cells from metabolic-induced DNA damage. Blood |